Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
November 08 2022 - 04:21PM
Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage
pharmaceutical company developing transformative therapies for
people suffering from diseases with high unmet medical needs, today
announced that the Adrian Adams, Chairman and Chief Executive
Officer, will participate in a fireside chat at the Guggenheim 4th
Annual Immunology and Neurology Day on Tuesday, November 15, 2022
at 1:00 p.m. ET in New York, NY.
A live webcast of the event will be available on
the Investors section of the Impel Pharmaceuticals website at
https://investors.impelpharma.com/. A replay of the presentation
will be available on the website for 90 days.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company
developing transformative therapies for people suffering from
diseases with high unmet medical needs. Impel offers, and is
developing, treatments that pair its proprietary POD® technology
with well-established therapeutics. In addition to Trudhesa® nasal
spray, which is approved in the U.S. for the acute treatment of
migraine with or without aura in adults. Impel is also developing
INP105 for the acute treatment of agitation and aggression in
patients with autism.
For additional information about Impel, please
visit www.ImpelPharma.com
Contact:
Media Relations:Melyssa
WeibleElixir Health Public RelationsPhone: (1)
386-366-0616Email: mweible@elixirhealthpr.com
Investor RelationsChristina TartagliaStern
Investor RelationsPhone: 212-362-1200Email:
christina.tartaglia@sternir.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Mar 2023 to Mar 2024